KAITLYN BOECKER — Lobbyist Profile | Poliscope

KAITLYN BOECKER

Filings

Clients

Firms

Years active

2015–2016

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
DRUG POLICY ALLIANCE	2	2015–2016

Lobbying firms

Firm	Filings	Years
DRUG POLICY ALLIANCE	2	2015–2016

Bills explicitly cited in this lobbyist’s assigned issues (6)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

H.R. 3537

Dangerous Synthetic Drug Control Act of 2016

Client: DRUG POLICY ALLIANCE · Firm: DRUG POLICY ALLIANCE

Open original LDA filing ↗

Cited source text

Opioid Overdose Reduction Act of 2014, issues related to overdose prevention. Overdose Prevention Act, issues related to overdose prevention. S. 524, Comprehensive Addiction Recovery Act Issues related to federal syringe funding ban S. 683, CARERS Act, issues related to medical marijuana. H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.

S. 524

Comprehensive Addiction and Recovery Act of 2016

Client: DRUG POLICY ALLIANCE · Firm: DRUG POLICY ALLIANCE

Open original LDA filing ↗

Cited source text

Original LDA source filings (2)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

DRUG POLICY ALLIANCE via DRUG POLICY ALLIANCE

2016 · first_quarter · Q1

Firm income: —Client expense: $90,000Open original LDA filing ↗

Assigned issues and filing targets (1 issues)

HCR

Health Issues

Opioid Overdose Reduction Act of 2014, issues related to overdose prevention. Overdose Prevention Act, issues related to overdose prevention. S. 524, Comprehensive Addiction Recovery Act Issues related to federal syringe funding ban S. 683, CARERS Act, issues related to medical marijuana. H.R. 3537, the Synthetic Drug Control Act of 2015, issues related to DEA authority.

Filing targets: HOUSE OF REPRESENTATIVES, SENATE

DRUG POLICY ALLIANCE via DRUG POLICY ALLIANCE

2015 · fourth_quarter · Q4

Source: Senate LDA